
Novel glucagon-like peptide 1 (GLP-1) рецептор агонист, displaying significantly elongated half-lives and improved long-acting antidiabetic activity in the presence of endogenous anti-DNP antibodies
Novel glucagon-like peptide 1 (GLP-1) receptor agonist, displaying significantly elongated half-lives and improved long-acting antidiabetic activity in the presence of endogenous anti-DNP antibodies
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.